Similar items over time

Drug - Valium 5 (Diazepam), Roche Australia, circa 1963 Object Reg. No: SH 850266

Summary:
Valium is the trade name given by Roche to the drug Diazepam, one of a group of drugs known as benzodiazepines. Benzodiazepines are known to variously possess anxiolytic, anticonvulsant, antidepressant, hypnotic and sedative properties. The first benzodiazepine, Librium, was developed in 1960 for the treatment of the symptoms of depression and anxiety but was surpassed in 1963 by Valium which was both safer and more potent than its predecessor. The development of the benzodiazepines in the 1960s was significant in the sense that they offered the first effective replacement for the heavier barbiturates that were used previously to help alleviate these symptoms. Valium was prescribed as a sedative in mental hospitals in Victoria.
Description:
Drug Valium (Diazepam) is contained in a small flat clear plastic box (sealed) with blue and white paper label under transparent top and bottom. Contains 90 pills.
Acquisition Information:
Donation from Office of Psychiatric Services
Discipline: History
Dimensions: 3.00 cm (Height), 1.00 cm (Width), 4.50 cm (Length)

More information

Tagged with: mental health, mental health institutions, psychiatric hospitals, psychiatric services, pharmaceuticals, medicines, hospitals, psychiatric institutions, medicinals drugs, drugs
Themes this item is part of: Psychiatric Services Collection, Medicine in Society Collection, Public Life & Institutions Collection
Primary Classification: MEDICINE & HEALTH
Secondary Classification: Mental Health - Pharmacy
Tertiary Classification: pharmaceuticals
Inscriptions: Text: Valium 5/ 90
Manufacturer: Roche, Australia, Circa 1963
Place Used: Victoria, Australia
References: Martindale. The extra pharmacopoeia, 26th ed. London Pharmaceutical Press. 1972.

Add your comment

  • Museum Victoria does not provide valuations, for more information please visit the valuation infosheet
  • Please note that Museum Victoria staff will not normally respond to comments posted on our website.
Yes No